미용 신경독 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of aesthetic neurotoxin Market

The global aesthetic neurotoxin market continues to expand due to rising demand for minimally invasive cosmetic procedures and increasing consumer acceptance of aesthetic enhancements. According to the report, the market was valued at USD 5.25 billion in 2024, is expected to reach USD 5.60 billion in 2025, and is projected to grow significantly to USD 9.12 billion by 2032, reflecting a CAGR of 7.2% during the forecast period. North America led the global market in 2024 with a 51.62% share, driven by advanced healthcare infrastructure, high patient spending, and strong adoption of aesthetic procedures.

Aesthetic neurotoxins, widely recognized as botulinum toxin injections, offer a non-surgical alternative for facial rejuvenation and wrinkle reduction. The increasing normalization of aesthetic procedures across generations and growing social acceptance of cosmetic enhancements are major contributors to market growth. Additionally, cosmetic tourism significantly boosts the industry, with countries like South Korea witnessing sharp increases in foreign patient visits-605,768 medical tourists in 2023, representing a 144.2% rise from 2022.

Market Dynamics

Market Drivers

Demand for minimally invasive aesthetic treatments continues to surge, particularly among younger consumers seeking early anti-aging interventions. The Aesthetic Society's 2022 report documented a 14% rise in total aesthetic procedures and a remarkable 23% growth in non-surgical treatments. Botulinum toxin injections remained the most popular, accounting for 8.87 million procedures in 2022. Rising disposable incomes in both developed and emerging economies further fuel the uptake of aesthetic neurotoxins.

Market Restraints

Despite strong demand, adverse effects associated with aesthetic neurotoxins-such as swelling, bruising, droopy eyelids, headaches, and temporary muscle weakness-pose restraints. High treatment costs also reduce accessibility. According to Direct Aesthetics PLLC, Botox treatments in the U.S. cost an average of USD 450, ranging from USD 200 to USD 1,200 per session. Such pricing limits access for lower-income patients and increases the risk of counterfeit product use.

Market Opportunities

R&D initiatives are expanding due to rising demand for safer, long-lasting, and less immunogenic neurotoxin formulations. Companies are developing new recombinant botulinum toxins designed to minimize adverse effects and extend cosmetic benefits. In October 2023, AbbVie announced positive Phase 3 results for trenibotulinumtoxinE (BoNT/E) for glabellar lines, highlighting ongoing innovation in product pipelines.

Market Challenges

The proliferation of counterfeit neurotoxin products poses a major risk to patient safety and diminishes trust in legitimate brands. The CDC reported in June 2024 that 17 individuals across nine U.S. states experienced harmful reactions after receiving counterfeit neurotoxin injections. Such incidents challenge revenue growth and reinforce the need for strict regulatory oversight.

Market Trends

Technological advancements-including the development of recombinant botulinum toxin-represent a major industry trend. Recombinant formulations are less immunogenic and offer safer alternatives with improved duration of effect. In September 2024, MingMed Biotechnology secured U.S. FDA IND approval for YY003, the first liquid recombinant BoNT/A for glabellar lines, demonstrating industry momentum toward next-generation neurotoxins.

Segmentation Insights

By Application

The glabellar lines segment dominated the market in 2024 due to high demand and robust clinical evidence supporting treatment effectiveness. Forehead wrinkles also recorded significant share, driven by the 2023 U.S. FDA approval of XEOMIN for multiple upper facial lines. The crow's feet segment continues to expand as these fine lines remain a common aesthetic concern.

By End-User

Specialty & dermatology clinics accounted for the largest revenue share in 2024. Their wide range of cosmetic services and strong participation in medical tourism drive patient preference. Hospitals & clinics also maintained a considerable share, with 24.5% of U.S. cosmetic procedures in 2023 performed in hospital settings.

Regional Insights

North America generated USD 2.71 billion in 2024, maintaining dominance due to high procedure volume and rapid regulatory approvals. The U.S. accounted for the majority of regional demand, with 4.4 million non-surgical aesthetic procedures in 2023.

Europe held substantial share fueled by aging demographics and strong adoption of skin rejuvenation treatments.

Asia Pacific is projected to grow at the fastest CAGR, supported by normalization of cosmetic procedures and major regional collaborations-such as the partnership between Huadong Medicine Aesthetics and ATGC Co. Ltd.

Latin America and Middle East & Africa show rising demand due to growing disposable income and product launches like Daewoong's NABOTA in Qatar (2025).

Conclusion

With market revenue rising from USD 5.25 billion in 2024 to USD 9.12 billion by 2032, the aesthetic neurotoxin industry is poised for strong growth. Increased acceptance of cosmetic enhancements, technological advancements, expanding medical tourism, and strategic industry partnerships will continue to shape the global landscape.

Segmentation By Application

• Forehead Wrinkles
• Glabellar Lines
• Crow's Feet
• Others

By End-User

• Specialty & Dermatology Clinics
• Hospitals & Clinics
• Others

By Region

• North America (By Application, End-User, and Country)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Application, End-User, and Country)
  • Germany (By Application)
  • U.K. (By Application)
  • France (By Application)
  • Italy (By Application)
  • Spain (By Application)
  • Scandinavia (By Application)
  • Ukraine (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Application, End-User, and Country /sub-region)
  • China (By Application)
  • India (By Application)
  • Japan (By Application)
  • Australia (By Application)
  • South Korea (By Application)
  • Thailand (By Application)
  • Taiwan (By Application)
  • Rest of the Asia Pacific (By Application)
• Latin America (By Application, End-User, and Country /sub-region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Colombia (By Application)
  • Argentina (By Application)
  • Venezuela (By Application)
  • Chile (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Application, End-User, and Country /sub-region)
  • UAE (By Application)
  • Saudi Arabia (By Application)
  • Rest of GCC (By Application)
  • South Africa (By Application)
  • Turkey (By Application)
  • Egypt (By Application)
  • Lebanon (By Application)
  • Iran (By Application)
  • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of the Number of Aesthetic Procedures, By Key Countries
• 4.2. Overview of Price Analysis of Types of Aesthetic Procedures
• 4.3. Overview of Regulatory Scenario, By Key Countries
• 4.4. Overview of Reimbursement Scenario, By Key Countries
• 4.5. New Product Launches, By Key Players
• 4.6. Pipeline Analysis, By Key Players
• 4.7. Imports/Sales Overview of Key Aesthetic Neurotoxin Products Approved by MHLW (Japan)

5. Global Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Application
  • 5.1.1. Forehead Wrinkles
  • 5.1.2. Glabellar Lines
  • 5.1.3. Crow's Feet
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By End-User
  • 5.2.1. Specialty & Dermatology Clinics
  • 5.2.2. Hospitals & Clinics
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Application
  • 6.1.1. Forehead Wrinkles
  • 6.1.2. Glabellar Lines
  • 6.1.3. Crow's Feet
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By End-User
  • 6.2.1. Specialty & Dermatology Clinics
  • 6.2.2. Hospitals & Clinics
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Application
  • 7.1.1. Forehead Wrinkles
  • 7.1.2. Glabellar Lines
  • 7.1.3. Crow's Feet
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By End-User
  • 7.2.1. Specialty & Dermatology Clinics
  • 7.2.2. Hospitals & Clinics
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Scandinavia
  • 7.3.7. Ukraine
  • 7.3.8. Rest of Europe

8. Asia Pacific Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Application
  • 8.1.1. Forehead Wrinkles
  • 8.1.2. Glabellar Lines
  • 8.1.3. Crow's Feet
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By End-User
  • 8.2.1. Specialty & Dermatology Clinics
  • 8.2.2. Hospitals & Clinics
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. South Korea
  • 8.3.6. Thailand
  • 8.3.7. Taiwan
  • 8.3.8. Rest of Asia Pacific

9. Latin America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Application
  • 9.1.1. Forehead Wrinkles
  • 9.1.2. Glabellar Lines
  • 9.1.3. Crow's Feet
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By End-User
  • 9.2.1. Specialty & Dermatology Clinics
  • 9.2.2. Hospitals & Clinics
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Chile
  • 9.3.4. Colombia
  • 9.3.5. Rest of Latin America

10. Middle East & Africa Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Application
  • 10.1.1. Forehead Wrinkles
  • 10.1.2. Glabellar Lines
  • 10.1.3. Crow's Feet
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By End-User
  • 10.2.1. Specialty & Dermatology Clinics
  • 10.2.2. Hospitals & Clinics
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. Egypt
  • 10.3.2. Iran
  • 10.3.3. Turkey
  • 10.3.4. Lebanon
  • 10.3.5. UAE
  • 10.3.6. Saudi Arabia
  • 10.3.7. South Africa
  • 10.3.8. Rest of Middle East and Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. AbbVie Inc. (Allergen Aesthetics)
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Ipsen Pharma
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merz Pharma
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. HUGEL, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Evolus, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. GALDERMA
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. REVANCE
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Supernus Pharmaceuticals, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Medytox
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. DAEWOONG PHARMACEUTICAL CO., LTD
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)